LONG MINI FUTURE WARRANT - ROCHE GS Share Price

Certificat

DE000GF47BB8

Market Closed - BOERSE MUENCHEN 19:27:00 20/06/2024 BST
11.77 EUR +0.09% Intraday chart for LONG MINI FUTURE WARRANT - ROCHE GS
Current month+22.86%
1 month+16.77%
Date Price Change
20/06/24 11.77 +0.09%
19/06/24 11.76 +1.38%
18/06/24 11.6 +1.93%
17/06/24 11.38 -0.61%
14/06/24 11.45 +1.33%

Real-time BOERSE MUENCHEN

Last update June 20, 2024 at 07:27 pm

More quotes

Static data

Product typeKnock-Out with Stop Loss
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer Goldman Sachs
WKN GF47BB
ISINDE000GF47BB8
Date issued 07/10/2020
Strike 138.1 CHF
Maturity Unlimited
Parity 10 : 1
Emission price 14.75
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 25.19
Lowest since issue 7.84

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
250 CHF
Average target price
278.1 CHF
Spread / Average Target
+11.22%
Consensus